A vaccine against Ebola: Problems and opportunities

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 5, 2015, Pages 1258-1260

  Rezza, Giovanni ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Ebola; Epidemiology; Ethics; Study design; Vectored vaccin

Indexed keywords

DNA VACCINE; EBOLA VACCINE;

ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; HUMAN; HUMORAL IMMUNITY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); AFRICA; DRUG DEVELOPMENT; EPIDEMIOLOGY; HEMORRHAGIC FEVER, EBOLA; IMMUNOLOGY; PROCEDURES; TRENDS;

AFRICA, WESTERN; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DISCOVERY; EBOLA VACCINES; HEMORRHAGIC FEVER, EBOLA; HUMANS;

EID: 84942428269     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1021528     Document Type: Article

References (25)

1. WHO. Response to the Ebola outbreak. Situation Report, January 21, 2015. http://www.who.int/csr/dis ease/ebola/situation-reports/en/. Access: January 27, 2015
2. Rezza G. Ebola: when a nightmare becomes reality. Ann Ist Super Sanitá 2014; 50:307-8; PMID:25522067; http://dx.doi.org/10.4415/ANN_14_04_01
3. Sullivan NJ, Sanchez A, Rollin PE, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9; PMID:11117750; http://dx.doi.org/10.1038/ 35046108
4. Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 2010; 29:304-13; PMID:21034824; http://dx.doi.org/ 10.1016/j.vaccine.2010.10.037
5. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-65; PMID:20463105; http://dx.doi.org/10.1128/ CVI.00131-10
6. Ledgerwood JE, DeZure AD, Stanley DA, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, Sitar S, et al. Chimpanzee adenovirus vector Ebola vaccine-Preliminary report. N Engl J Med 2014; DOI: 10.1056/NEJMoa1410863; PMID:25426834
7. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by animal rule. Nat Rev Microbiol 2009; 7:684; http://dx.doi.org/10.1038/ nrmicro2129
8. Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus chellange. Nat Med 2014 Oct 20(10): 1126-29; Epub 2014 Sep 7; PMID:25194571; http://dx.doi.org/10.1038/nm.3702
9. Rampling T, Ewer K, Bowyer G, Wright D, Imoukhuede EB, Payne R, Hartnell F, Gibani M, Bliss C, Minhinnick A, et al. A monovalent chimpanzee adenovirus Ebola vaccine-Preliminary report. N Engl J Med 2015; PMID:25629663; http://dx.doi.org/10.1056/ NEJMoa1411627
10. Bausch DG. One step closer to an Ebola virus vaccine. N Engl J Med 2014; PMID:25426836; http://dx.doi. org/10.1056/NEJMe141305
11. Kibuuka H, Berkowitz NM, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: phase 1b, randomized, double-blind, placebo-controlled clinical trial. Lancet 2014; PMID:25540891; http://dx.doi.org/10.1016/50140-6736(14)62385-0
12. Sridhar S. Ebola and Marburg vaccines for Africa: one step closer. Lancet 2014; PMID:25540890; http://dx. doi.org/10.1016/S0140-6736(14)62445-4
13. WHO. Experimental Ebola vaccines. Ebola situation assessment-1 October 2014. http://www.who.int/ mediacentre/news/ebola/01-october-2014/en/index2. html. Access: 08/01/2015
14. Johnson & Johnson. Johnson & johnson announces major commitment to speed Ebola vaccine development and significantly Expand Production.http://www.jnj.com/news/all/Johnson-Johnson-Announces-Major-Commitment-to-Speed-Ebola-Vaccine-Develop ment-and-Significantly-Expand-Production. Last update 1-12-2015
15. Muhammadi D. Ebola vaccine trials back on track. Lancet 2015; 385:214-5; PMID:25601786; http://dx. doi.org/10.1016/S0140-6736(15)60035-6
16. Marzi A, Feldman H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines 2014; 13:521-31; PMID:24575870; http://dx.doi.org/ 10.1586/14760584.2014.885841
17. Cohen J. Ebola vaccine: little and late. Science 204; 345:1441-2; PMID:25237082; http://dx.doi.org/ 10.1126/science.345.6203.1441
18. Kanapathipillai R, Rastrepo AMH, Fast P, Wood D, Dye C, Kieny MP, Moorthy V. Ebola vaccine-an urgent priority. N Engl J Med 2014; 371:2249-51; PMID:25289888; http://dx.doi.org/10.1056/ NEJMp1412166
19. Tully CM, Lambe T, Gilbert SC, Hill AVS. Emergency ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. Lancet 2015. http://dx.doi.org/10.1016/S1473-3099(14) 71071-0; PMID:25595637
20. Cohen J. Ebola vaccines racing forward at record pace. Science 2014; 345:1228-9; PMID:25214582; http:// dx.doi.org/10.1126/science.345.6202.1228
21. Cohen J, Kupferschmidt. Ebola vaccine trials raise ethical issues. Science 2014; 346:289-90; PMID:25324364; http://dx.doi.org/10.1126/ science.346.6207.289
22. CIDRAP. Wellcome Trust. Fast-track development of Ebola vaccines. January 12, 2015. http://www.cidrap. umn.edu/news-perspective/2015/01/report-maps-com plex-challenges-ebola-vaccine-efforts
23. Cooper CL, Bavari S. A race for an Ebola vaccine: promises and obstacles. Trends in Microbiology 2014; 23:65-6. PMID:25535021; http://dx.doi.org/10.1016/ j.tim.2014.12.005
24. Woodall J, Feldman R. Ebola update 16. ProMEDmail, January 17, 2015. http://www.promedmail.org/
25. Lee BY, Moss WJ, Privor-Dumm L, Constenla DO, Knoll MD, O'Brien KL. Is the world ready for an Ebola vaccine? Lancet 2015; 385:203-4; PMID:25706696; http://dx.doi.org/10.1016/S0140-6736(14)62398-9